CoChat

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

Background Abiraterone acetate plus prednisone significantly improved radiographic progression-free survival compared with placebo plus prednisone in men with chemotherapy-naive castration-resistant prostate cancer at the interim analyses of the COU-AA-302 trial. Here, we present the prespecified final analysis of the trial, assessing the effect of abiraterone acetate plus prednisone on overall survival, time to opiate use, and use of other subsequent therapies.Methods In this placebo-controlled, double-blind, randomised phase 3 study, 1088 asymptomatic or mildly symptomatic patients with chemotherapy-naive prostate cancer stratified by Eastern Cooperative Oncology performance status (0 vs 1) were randomly assigned with a permuted block allocation scheme via a web response system in a 1:1 ratio to receive either abiraterone acetate (1000 mg once daily) plus prednisone (5 mg twice daily; abiraterone acetate group) or placebo plus prednisone (placebo group). Coprimary endpoints were radiographic progression-free survival and overall survival analysed in the intention-to-treat population. The study is registered with ClinicalTrials.gov, number NCT00887198.Findings At a median follow-up of 49.2 months (IQR 47.0-51.8), 741 (96%) of the prespecified 773 death events for the final analysis had been observed: 354 (65%) of 546 patients in the abiraterone acetate group and 387 (71%) of 542 in the placebo group. 238 (44%) patients initially receiving prednisone alone subsequently received abiraterone acetate plus prednisone as crossover per protocol (93 patients) or as subsequent therapy (145 patients). Overall, 365 (67%) patients in the abiraterone acetate group and 435 (80%) in the placebo group received subsequent treatment with one or more approved agents. Median overall survival was significantly longer in the abiraterone acetate group than in the placebo group (34.7 months [95% CI 32.7-36.8] vs 30.3 months [28.7-33.3]; hazard ratio 0.81 [95% CI 0.70-0.93]; p=0.0033). The most common grade 3-4 adverse events of special interest were cardiac disorders (41 [8%] of 542 patients in the abiraterone acetate group vs 20 [4%] of 540 patients in the placebo group), increased alanine aminotransferase (32 [6%] vs four [<1%]), and hypertension (25 [5%] vs 17 [3%]).Interpretation In this randomised phase 3 trial with a median follow-up of more than 4 years, treatment with abiraterone acetate prolonged overall survival compared with prednisone alone by a margin that was both clinically and statistically significant. These results further support the favourable safety profile of abiraterone acetate in patients with chemotherapy-naive metastatic castration-resistant prostate cancer.Funding Janssen Research & Development.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(14)71205-7

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 26 references

Research works printed but not linked: 1

  1. Bellmunt, 2013, Impact of prior antiandrogen exposure on clinical outcomes in patients receiving abiraterone acetate: results from a randomized study (COU-AA-301) in metastatic castration-resistant prostate cancer post-docetaxel, Ann Oncol, 24

Cited by

See all 1,369

Metadata

Authors
Ryan, C. J., Smith, M. R., Fizazi, K., Saad, F., Mulders, P. F. A., Sternberg, C. N., Miller, K., Logothetis, C. J., Shore, N. D., Small, E. J., Carles, J., Flaig, T. W., Taplin, M.-E., Higano, C. S., de Souza, P., de Bono, J. S., Griffin, T. W., De Porre, P., Yu, M. K., Park, Y. C., Li, J., Kheoh, T., Naini, V., Molina, A., & Rathkopf, D. E.
Affiliations
  • University of California, San Francisco (US)
  • Harvard University (US)
  • Université Paris-Sud (FR)
  • Radboud University Medical Center (NL)
  • Azienda Ospedaliera San Camillo-Forlanini (IT)
  • Charité – Universitätsmedizin Berlin (DE)
  • The University of Texas MD Anderson Cancer Center (US)
  • Carolina Urologic Research Center (US)
  • Vall d'Hebron Hospital Universitari (ES)
  • University of Colorado Cancer Center (US)
  • University of Washington (US)
  • Janssen Research & Development (United States) (US)
  • Memorial Sloan Kettering Cancer Center (US)
Corresponding author
Ryan, Charles J
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2015-02
Volume
16
Issue
2
Pages
152-160
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2055346449
Cited by
1,369
References
25
Citations by year
2026: 61 · 2025: 97 · 2024: 108 · 2023: 93 · 2022: 90 · 2021: 151 · 2020: 153 · 2019: 125 · 2018: 137 · 2017: 136 · 2016: 135 · 2015: 78
FWCI
128.14
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
  • Radboud Repository (Radboud University) (submittedVersion)
Funders
Janssen Research and Development
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Health Sciences › Medicine › Oncology › Bone health and treatments
  • Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
Keywords
abiraterone, prednisone, castration-resistant prostate cancer, metastatic prostate cancer, chemotherapy-naive patients, overall survival, progression-free survival, subsequent therapy, androgen receptor antagonists, corticosteroid adjuvant therapy
MeSH terms
Aged, Androstenes, Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms, Double-Blind Method, Follow-Up Studies, Humans, Male, Neoplasm Staging, Prednisone, Prognosis, Survival Rate, Disease Progression, Antineoplastic Agents, Hormonal, Prostatic Neoplasms, Castration-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. https://app.cochat.ai/papers/10.1016/s1470-2045(14)71205-7
The paper
Ryan, C. J., Smith, M. R., Fizazi, K., Saad, F., Mulders, P. F. A., Sternberg, C. N., Miller, K., Logothetis, C. J., Shore, N. D., Small, E. J., Carles, J., Flaig, T. W., Taplin, M.-E., Higano, C. S., de Souza, P., de Bono, J. S., Griffin, T. W., De Porre, P., Yu, M. K., . . . Rathkopf, D. E. (2015). Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(14)71205-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.